靶向结直肠癌中的表皮生长因子受体（EGFR） - Suppr

Targeting EGFR in colorectal cancer.

作者信息

Messersmith Wells A, Ahnen Dennis J

出版信息

N Engl J Med. 2008 Oct 23;359(17):1834-6. doi: 10.1056/NEJMe0806778.

DOI:10.1056/NEJMe0806778

PMID:18946069

Abstract

摘要

相似文献

Targeting EGFR in colorectal cancer.

N Engl J Med. 2008 Oct 23;359(17):1834-6. doi: 10.1056/NEJMe0806778.

To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.

Clin Colorectal Cancer. 2012 Jun;11(2):85-7. doi: 10.1016/j.clcc.2011.10.005. Epub 2011 Dec 9.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

Cetuximab for metastatic colorectal cancer.

N Engl J Med. 2009 Jul 2;361(1):96; author reply 96-7.

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Eur J Cancer. 2015 Mar;51(5):587-94. doi: 10.1016/j.ejca.2015.01.054. Epub 2015 Feb 9.

K-Ras mutations are changing practice in advanced colorectal cancer.

J Natl Cancer Inst. 2008 Dec 3;100(23):1667-9. doi: 10.1093/jnci/djn429. Epub 2008 Nov 25.

[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].

Gan To Kagaku Ryoho. 2010 May;37(5):791-4.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Cancer Res. 2009 Mar 1;69(5):1851-7. doi: 10.1158/0008-5472.CAN-08-2466. Epub 2009 Feb 17.

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.

Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742.

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.

Cancer Treat Rev. 2009 May;35(3):262-71. doi: 10.1016/j.ctrv.2008.11.005. Epub 2008 Dec 30.

引用本文的文献

Drug Molecule Recruitment Empowered by Phase Separation on Cell Membranes .

JACS Au. 2025 May 24;5(6):2567-2579. doi: 10.1021/jacsau.5c00197. eCollection 2025 Jun 23.

Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf.

Pharmaceuticals (Basel). 2025 Jun 14;18(6):895. doi: 10.3390/ph18060895.

Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors.

Nat Commun. 2025 Apr 29;16(1):4028. doi: 10.1038/s41467-025-59377-y.

DEPTOR suppresses lymphomagenesis by promoting EGFR degradation via HUWE1 E3 ligase.

Cell Death Differ. 2025 Apr 1. doi: 10.1038/s41418-025-01497-5.

Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

J Gastrointest Cancer. 2024 Oct 22;56(1):9. doi: 10.1007/s12029-024-01128-1.

Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.

Cancer Treat Res. 2024;192:305-418. doi: 10.1007/978-3-031-61238-1_15.

A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer.

Cancer Res Treat. 2024 Apr;56(2):590-601. doi: 10.4143/crt.2023.1117. Epub 2023 Dec 7.

Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.

Front Immunol. 2023 Aug 9;14:1207276. doi: 10.3389/fimmu.2023.1207276. eCollection 2023.

Feature selection translates drug response predictors from cell lines to patients.

Front Genet. 2023 Jul 14;14:1217414. doi: 10.3389/fgene.2023.1217414. eCollection 2023.

Direct ring-strain loading for visible-light accelerated bioorthogonal ligation via diarylsydnone-dibenzo[b,f ][1,4,5]thiadiazepine photo-click reactions.

Commun Chem. 2020 Mar 4;3(1):29. doi: 10.1038/s42004-020-0273-6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Targeting EGFR in colorectal cancer.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献